Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Author:
Funder
Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00228-023-03561-w.pdf
Reference39 articles.
1. Han SK, Baik SK, Kim MY (2023) Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol 29(suppl):S5-s16
2. Watt MJ, Miotto PM, De Nardo W, Montgomery MK (2019) The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev 40(5):1367–1393
3. Cotter TG, Rinella M (2020) Non-alcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 158(7):1851–1864
4. Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212–2224
5. Ferguson D, Finck BN (2021) Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 17(8):484–495
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3